Abstract
Purpose
A series of melanocortin-4 receptor (MC4R) agonists, developed for use as anti-obesity agents, were found to have unusual pharmacokinetic behavior arising from excessive retention in the liver, with nearly undetectable levels in plasma following oral administration in mice. This work investigates the molecular basis of the prolonged liver retention that provided a rational basis for the design of an analog with improved behavior.
Materials and Methods
The livers of mice were harvested and techniques were utilized to fractionate them into pools differentially enriched in organelles. The distribution of organelles in the fractions was determined using organelle-specific enzymatic assays. Livers from mice dosed with drug were fractionated and comparisons with organelle distributions assisted in determining the subcellular localization of the drug. Further analysis in cell culture systems was used to confirm results from liver fractionation studies and also allowed for more extensive evaluations to examine the mechanism for organelle compartmentalization
Results
Fractionation of livers following oral administration of the agonist showed sequestration in lysosomes. Subsequent evaluations in a cell culture system confirmed this finding. Agents used to disrupt acidification of lysosomes led to decreased lysosomal accumulation of the drug, which implicated a pH-partitioning type sequestration mechanism. These findings led to the rational synthesis of an analog of the parent compound with properties that reduced lysosomal sequestration. When this compound was examined in mice, the liver retention was found to be greatly reduced and plasma levels were significantly elevated relative to the parent compound.
Conclusions
Weakly basic drugs with optimal physicochemical properties can be extensively sequestered into lysosomes according to a pH-partitioning type mechanism. When administered orally in animals, this particular sequestration event can manifest itself in long term retention in the liver and negligible levels in blood. This work revealed the mechanism for liver retention and provided a rational platform for the design of a new analog with decreased liver accumulation and better opportunity for pharmacokinetic analysis and therapeutic activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
K. Yokogawa, J. Ishizaki, S. Ohkuma, and K. Miyamoto. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find. Exp. Clin. Pharmacol. 24:81–93 (2002).
M. Duvvuri, W. Feng, A. Mathis, and J. P. Krise. A cell fractionation approach for the quantitative analysis of subcellular drug disposition. Pharm. Res. 21:26–32 (2004).
M. Duvvuri and J. P. Krise. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol. Pharm. 2:440–448 (2005).
Y. Gong, M. Duvvuri, and J. P. Krise. Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J. Biol. Chem. 278:50234–50239 (2003).
W. A. Daniel and J. Wojcikowski. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol. Toxicol. 80:62–68 (1997).
J. Ishizaki, K. Yokogawa, F. Ichimura, and S. Ohkuma. Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. J. Pharmacol. Exp. Ther. 294:1088–1098 (2000).
R. Safaei, K. Katano, B. J. Larson, G. Samimi, A. K. Holzer, W. Naerdemann, M. Tomioka, M. Goodman, and S. B. Howell. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin. Cancer Res. 11:756–767 (2005).
R. M. Sandoval and B. A. Molitoris. Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am. J. Physiol. Renal. Physiol. 286:F617–624 (2004).
C. de Duve, T. de Barsy, B. Poole, A. Trouet, P. Tulkens, and F. Van Hoof. Commentary. Lysosomotropic agents. Biochem. Pharmacol. 23:2495–2531 (1974).
K. Tanigaki, S. Sasaki, and S. Ohkuma. In bafilomycin A1-resistant cells, bafilomycin A1 raised lysosomal pH and both prodigiosins and concanamycin A inhibited growth through apoptosis. FEBS Lett. 537:79–84 (2003).
M. Schindler, S. Grabski, E. Hoff, and S. M. Simon. Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 35:2811–2817 (1996).
M. Duvvuri, S. Konkar, R. S. Funk, J. M. Krise, and J. P. Krise. A chemical strategy to manipulate the intracellular localization of drugs in resistant cancer cells. Biochemistry 44:15743–15749 (2005).
M. Duvvuri, Y. Gong, D. Chatterji, and J. P. Krise. Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60. J. Biol. Chem. 279:32367–32372 (2004).
K. Shedden, X. T. Xie, P. Chandaroy, Y. T. Chang, and G. R. Rosania. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 63:4331–4337 (2003).
M. Duvvuri, S. V. Konkar, K. H. Hong, B. S. J. Blagg, and J. P. Krise. A new approach for enhancing differential selectivity of drugs to cancer cells. Chem. Biol. 1:309–315 (2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gong, Y., Zhao, Z., McConn, D.J. et al. Lysosomes Contribute to Anomalous Pharmacokinetic Behavior of Melanocortin-4 Receptor Agonists. Pharm Res 24, 1138–1144 (2007). https://doi.org/10.1007/s11095-007-9239-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-007-9239-y